GlobeNewswire

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04/11/2026
CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immune-mediated diseases, today [...]
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026
04/11/2026
Announced updated clinical data in more than 80 patients from the ongoing PiNACLE pivotal trial in patients with 3L+ R/R LBCL and from the Phase 1/2 trial 2L cohort of ronde-cel in abstracts accepted for presentation at [...]
Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
04/11/2026
NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a late-stage clinical oncology company focused on keeping cancer patients alive and helping them thrive, today announced that [...]
Cytek Biosciences Reports Third Quarter 2026 Financial Results
04/11/2026
FREMONT, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third [...]
Alamar Biosciences to Participate in Upcoming Investor Conferences
04/11/2026
Fremont, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Alamar Biosciences, Inc. (Nasdaq: ALMR), a leader in precision proteomics dedicated to enabling the earliest detection of disease, today announced the company will be [...]
Kailera Reports Third Quarter 2026 Financial Results and Provides Business Updates
04/11/2026
Ribupatide oral global Phase 3 program expected to begin in 1H 2027 following completion of End-of-Phase 2 meeting with FDA Ribupatide injection Phase 2b trial and KaiNETIC global Phase 3 program fully enrolled; data [...]
Damora Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
04/11/2026
-- CLARITY-101 Phase 1/1b clinical trial initiated and cleared by multiple global regulatory authorities, including the U.S. Food and Drug Administration (FDA) -- -- New preclinical data highlighting DMR-001’s [...]
Annovis Announces Launch of Proposed Public Offering
04/11/2026
MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for [...]
Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates
04/11/2026
- Duchenne (SGT-003): SGT-003 has been generally well tolerated in the 53 participants dosed in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of November 3, 2026 - - Solid has scheduled a Type C meeting with the FDA [...]
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04/11/2026
BOSTON, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that, on November 1, 2026, the [...]
OPKO Health Reports Third Quarter 2026 Business Highlights and Financial Results
04/11/2026
Conference Call to Begin Today at 4:30 p.m. ET MIAMI, Nov. 04, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a multinational biopharmaceutical company, today reports business highlights and financial results [...]
FocalTherics™ to Participate in Upcoming Investor Conferences
04/11/2026
FocalTherics ™ to Participate in Upcoming Investor Conferences AUSTIN, Texas, Nov. 04, 2026 (GLOBE NEWSWIRE) -- FocalTherics (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced that [...]
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04/11/2026
MALVERN, Pa., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health and provider of NeuroStar ® TMS technology and direct patient care through the Greenbrook [...]
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
04/11/2026
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 04 nov. 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]
Monthly information on share capital and company voting rights
04/11/2026
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]
STERIS Announces Financial Results for Fiscal 2027 Second Quarter
04/11/2026
Fiscal 2027 second quarter revenue increased 9%; constant currency organic revenue growth was 8% Fiscal 2027 second quarter as reported diluted EPS increased to $2.19; adjusted EPS per diluted share increased to $2.94 [...]
Edesa Biotech to Present at Guggenheim Healthcare Innovation Conference
04/11/2026
TORONTO, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Edesa Biotech, Inc. (Nasdaq: EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today [...]
Eton Pharmaceuticals to Present at 2026 Jefferies Global Healthcare Conference in London
04/11/2026
DEER PARK, Ill., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare [...]
Moleculin Announces Acceptance of Annamycin Data for Presentation at the 2026 American Society of Hematology (ASH) Annual Meeting
04/11/2026
First interim results from pivotal Phase 2/3 trial highlight encouraging remission rates in patients with relapsed or refractory AML HOUSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. (Nasdaq: MBRX) (“ [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum